Status:
COMPLETED
Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborating Sponsors:
Disarm Therapeutics
Conditions:
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This pilot study will attempt to establish the feasibility of using tissue oxygen measurements and the protein, neurofilament light chain (NF-L), as potential biomarkers for chemotherapy-induced perip...
Detailed Description
Therapy with chemotherapeutic drugs can make a huge impact on survival and quality of life in patients with cancer. Advances in medical monitoring and the effectiveness of these therapies have signifi...
Eligibility Criteria
Inclusion
- Scheduled to receive chemotherapy with taxane compounds for the treatment of breast cancer.
- No prior taxane or platinum chemotherapy prior to enrollment.
- Life expectancy greater than or equal to 12 months.
- Able to provide independent informed consent for the study.
- Able to undergo EPR oximetry
- Age 18 years or older
Exclusion
- Central nervous system or other impairments that interfere with clinical and electrophysiological assessment.
- Unable to provide independent informed consent.
- Pacemaker or other metallic objects that would be contraindicated for MRI.
- A requirement for supplemental oxygen at baseline, or known, severe chronic obstructive pulmonary disease .
- Previous exposure to neurotoxic chemotherapeutic agents.
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2022
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03348956
Start Date
March 1 2018
End Date
February 14 2022
Last Update
June 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth-Hitchcock Medical Center in Lebanon, NH
Lebanon, New Hampshire, United States, 03766